90% of drug candidates fail in clinical trials. Not because scientists aren't brilliant enough — but because the way we discover drugs is still fundamentally an industrial-era method. GenTide exists to change that. 全球每年有超过 90% 的药物候选化合物在临床试验中失败。不是因为科学家不够聪明， 而是因为我们发现药物的方式，本质上还是工业时代的方法。GenTide 存在，是为了改变这一切。
Every year, hundreds of millions of patients wait for a therapy that doesn't exist yet. Many diseases are declared "untreatable" — not because there is no solution, but because the tools available haven't been able to find one. 每年有数亿患者在等待一款针对自己疾病的有效药物。很多疾病被宣判为"无药可治"， 不是因为没有解法，而是因为现有的工具和方法还找不到它。
AI doesn't just make drug discovery "a bit faster." It fundamentally changes the boundaries of what's possible. When a model can design a thousand candidate molecules in an hour, when structural biology at atomic resolution validates binding in weeks instead of years, when every failed experiment becomes training data for the next success — those "untreatable" diseases start to have answers. AI 不只是让药物发现变得"快一点"——它从根本上改变了可能性的边界。 当一台机器可以在一小时内设计出一千个候选分子，当冷冻电镜能在几周内完成过去 需要几年的结构解析，当每一次实验失败都变成下一次成功的训练数据—— 那些曾经"无药可治"的疾病，开始有了答案。
GenTide exists to accelerate this transformation. GenTide 存在，是为了加速这个转变的到来。
A company without a clear set of beliefs is just a collection of activities. These four beliefs shape every decision we make at GenTide. 没有信念的公司，只是一堆活动的集合。这四条信念塑造了睿联每一个决策。
Intuition matters, but data matters more. We believe in AI-assisted systematic discovery over isolated flashes of genius. A well-designed DTBL closed loop is more reliable than a hundred clever guesses. 直觉很重要，但数据更重要。我们相信 AI 辅助的系统性发现，而非孤立的天才灵感。 一个设计良好的 DTBL 闭环，比一百个聪明的猜测更可靠。
Every year shaved off R&D timelines means more patients don't have to exhaust their hope waiting. We don't treat speed as a business metric — we treat it as part of the mission itself. 每缩短一年的研发周期，就意味着有更多患者不必在等待中耗尽希望。 我们不把速度当作商业指标，而把它当作使命的一部分。
Any individual drug can fail. But a genuinely effective AI discovery platform continues to generate new answers. GenTide's core asset is capability, not any single molecule. 任何一款药物都可能失败，但一个真正有效的 AI 发现平台， 能持续产生新的答案。GenTide 的核心资产是能力，不是某个分子。
Choosing AI-Native means assuming from day one that AI is the underlying infrastructure of company operations — not layering AI onto old workflows, but redesigning every workflow with AI as the default. 选择 AI-Native，意味着从第一天起就假设 AI 是公司运营的底层基础设施。 不是在旧流程上叠加 AI，而是以 AI 为前提重新设计每一个流程。
Make the DTBL platform a trusted discovery engine — validated by real commercial partnerships把 DTBL 平台做成真正可信赖的发现引擎，以实际商业合作验证平台价值
Advance differentiated pipelines to IND — proving AI-designed molecules have real-world value推进差异化管线走到 IND，用真实临床前数据证明 AI 设计分子的价值
Build an AI-Native organization — where every function defaults to AI as its operating layer建立 AI-Native 组织底座，让公司每个职能以 AI 为默认操作层
Ten years from now: GenTide's DTBL platform powers the discovery engine of multiple top-tier global pharma companies. At least one independently-discovered program is approved and on the market. The β2-AR anti-aging mechanism has defined a new therapeutic paradigm for aging medicine. And GenTide's name has become synonymous with "AI-Native drug discovery" — not because we are the largest, but because we defined how it should be done. 10 年后：GenTide 的 DTBL 平台成为数家全球顶级药企的核心发现引擎。 我们自主发现的至少一条管线在全球市场上市，证明 AI 能设计更好的药物。 β2-AR 抗衰老机制催生了全新的老龄化医学治疗范式。GenTide 的名字， 成为"AI-Native 药物发现"这个品类的代名词——不是因为我们最大， 而是因为我们定义了这件事应该怎么做。
AlphaFold 3, Boltz-2, and diffusion generative models have moved AI-assisted drug discovery from "proof of concept" to "early clinical validation." The first fully AI-designed drug has published Phase IIa positive data in Nature Medicine. The direction is confirmed — but the competitive landscape is not yet fixed. AlphaFold 3、Boltz-2、扩散生成模型相继突破，让 AI 辅助药物发现从"概念验证" 进入"早期临床验证"阶段。首个完全由 AI 设计的药物已在《自然·医学》发表 IIa 期阳性数据。行业已经确认方向，但真正的竞争格局还未固化。
Companies founded today have an advantage that no established pharma can acquire: no legacy workflows, no organizational politics, no legacy IT. GenTide can build AI into every workflow from scratch — not patch it onto an old system. Google needed 18–24 months of painful transformation to catch the AI wave. Traditional pharma will pay the same, or higher, price. 现在成立的公司有一个老牌药企永远无法获得的优势：没有遗留工作流， 没有组织政治，没有遗留 IT 系统。GenTide 可以从零开始把 AI 设计进每一个工作流， 而不是在旧系统上打补丁。Google 花了 18–24 个月痛苦转型才追上 AI 浪潮。 传统药企的代价只会更高。
This AI-Native advantage is a one-time opportunity. Once a company grows, organizational inertia makes any change expensive. The most critical and irreversible window for building an AI-Native culture is right now — before scale, before hierarchy, before habit. 这个优势是一次性的。等公司大了，组织惯性会让任何改变都变得昂贵。 现在是建立 AI-Native 文化最关键也最不可逆的窗口——在规模化之前， 在层级固化之前，在习惯形成之前。